Abstracts tagged "Systemic sclerosis"

Abstract Number: 0644 • ACR Convergence 2023
Prediction of Stable SSc-ILD Depends on Definition of ILD Progression
Anna-Maria Hoffmann-Vold¹, Liubov Petelytska², Havard Fretheim¹, Trond Mogens Aaløkken³, Mike Becker⁴, Cathrine Brunborg⁵, Cosimo Bruni⁶, Christian Clarenbach⁷, Phuong Phuong Diep⁸, Rucsandra Dobrota⁶, Michael Durheim⁹, Muriel Elhai¹⁰, Thomas Frauenfelder¹¹, Suzana Jordan⁶, Emily Langballe¹², Carina Mihai⁶, Oyvind Midtvedt¹, Oyvind Molberg¹³ and Oliver Distler⁶, ¹Oslo University Hospital, Oslo, Norway, ²Bogomolets National Medical University, Kyiv, Ukraine, ³Dept of Radiology, Oslo University Hospital, Oslo, Norway, ⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁵Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital - Rikshospitalet, Oslo, Norway, ⁶Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁷Dept of Pulmonology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁸Dept of Respiratory diseases, University Hospital Oslo, Oslo, Norway, ⁹Dept of Respiratory diseases, Oslo University Hospital, Oslo, Norway, ¹⁰University Hospital zurich, University of Zurich, Zurich, Switzerland, ¹¹Dept of Radiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ¹²Universitetet i Oslo, Oslo, Norway, ¹³Dept of Rheumatology, University Hospital Oslo, Oslo, Norway
Background/Purpose: Progression of interstitial lung disease (ILD) reduces long-term survival in patients with systemic sclerosis (SSc), and aggressive treatment and tight monitoring should be considered.…
Abstract Number: 0666 • ACR Convergence 2023
Troponin I Levels in Systemic Sclerosis Patients with Myocardial Involvement
Eva Hoekstra¹, Sophie Liem¹, Nivine Levarht¹, Cynthia Fehres¹, Saad Ahmed¹, Nina Ajmone Marsan², Thomas Huizinga¹ and Jeska de Vries-Bouwstra¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Department of Cardiology, Heart Lung Centre, Leiden University Medical Centre, Leiden, Netherlands
Background/Purpose: As primary myocardial involvement in systemic sclerosis (SSc) is associated with worse prognosis, research on diagnostic tools for recognition is essential. Troponin I was…
Abstract Number: 0940 • ACR Convergence 2023
A Novel Therapeutic Opportunity in Systemic Sclerosis: The Fibrolytic Activities of a Specialized Macrophage Secretome
Françis Bonnefoy¹, Susanne Behlke² and Sylvain Perruche¹, ¹Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Institute/MedINNPharma, Besançon, France, ²MedINNPharma, Besançon, France
Background/Purpose: Systemic sclerosis (SSc) a complex and rare immune-mediated connective tissue disorder characterized by microvascular damage, inflammatory cell infiltration, and excessive deposition of extracellular matrix…
Abstract Number: 1035 • ACR Convergence 2023
Diagnostic and Educational Utility of an Ultrasound Protocol for Evaluation of Hand Pain in Systemic Sclerosis
Meridith Balbach, Tracy Frech, Nicholson Chadwick, Kevin Byram and Erin Chew, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Hand impairment is a prevalent issue among systemic sclerosis (SSc) patients and contributes to disability and diminished quality of life. Managing hand pain can…
Abstract Number: 1533 • ACR Convergence 2023
Long-term Use of Rituximab in Systemic Sclerosis: A Real-life Italian Multicentre Study
Giacomo De Luca¹, Corrado Campochiaro², Fabio Cacciapaglia³, Nicoletta Del Papa⁴, Elisabetta Zanatta⁵, Paolo Airò⁶, Maria Grazia Lazzaroni⁶, Dilia Giuggioli⁷, Maria De Santis⁸, Gabriella Alonzi⁹, Stefano Stano¹⁰, Marco Binda⁵, Beatrice Moccaldi⁵, Antonio Tonutti¹¹, Florenzo Iannone¹², Maria Antonietta D'Agostino⁹, Lorenzo Dagna¹³, marco Matucci Cerinic¹⁴ and Silvia Bosello¹⁵, ¹Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milano, Italy, ²IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Disease. Vita-Salute San Raffaele University, Milan, Italy, ³Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari, Bari, Italy, ⁴Scleroderma Clinic, Dipartimento di Reumatologia, ASST Gaetano Pini CTO, Milano, Italy, ⁵Rheumatology Unit, Padova University Hospital, Padova, Italy, ⁶Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy, ⁷Scleroderma Unit, Rheumatology Unit, University Hospital of Modena and Reggio Emilia, Modena, Italy, ⁸Reumatologia e Immunologia Clinica, IRCCS Humanitas Research Hospital, Humanitas University, Rozzano, Milan, Italy, ⁹Scleroderma Unit, Division of Rheumatology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ¹⁰Rheumatology Unit - DiMePRe-J University of Bari, Bari, Italy, ¹¹Humanitas University and Humanitas Research Hospital, Rozzano, Italy, ¹²Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Bari, Italy, ¹³Department of Internal Medicine, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy, ¹⁴Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Milan, Italy, ¹⁵Division of Rheumatology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy
Background/Purpose: Rituximab(RTX) has been used for the management of systemic sclerosis(SSc). Its efficacy has been recently confirmed in a phase III clinical trial with extension…
Abstract Number: 2094 • ACR Convergence 2023
Increasing Collaboration, Education, and Awareness of Scleroderma Through an Interprofessional Education Program: Emphasizing the Importance of a Multidisciplinary Team and the Patient as the Primary Educator
Corey Fellon¹, Hannah Bowen² and Lee Shapiro³, ¹Albany Medical College, Albany, NY, ²Steffens Scleroderma Foundation, Batavia, NY, ³Albany Medical College, Stillwater, NY
Background/Purpose: Scleroderma is a condition that can affect almost every organ system and thus requires an interprofessional team to optimally manage symptoms and improve patient…
Abstract Number: 2594 • ACR Convergence 2023
Trajectories of Forced Vital Capacity (FVC) in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Oliver Distler¹, Madelon Vonk², Arata Azuma³, Maureen Mayes⁴, Dinesh Khanna⁵, Kristin B Highland⁶, Gerrit Toenges⁷, Margarida Alves⁸ and Yannick Allanore⁹, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ²Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Pulmonary Medicine and Oncology, Nippon Medical School, Tokyo, Japan, and Meisei Hospital, Saitama, Japan, ⁴Division of Rheumatology, University of Texas McGovern Medical School, Houston, TX, ⁵University of Michigan, Ann Arbor, MI, ⁶Cleveland Clinic, Cleveland, OH, ⁷Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany, ⁸Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, ⁹Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France
Background/Purpose: The SENSCIS trial enrolled patients with SSc-ILD without a requirement for them to have evidence of recent progression. During the trial, nintedanib reduced the…
Abstract Number: 0266 • ACR Convergence 2023
E-selectin, ICAM-1 and ET-1 Biomarkers Address the Concern of the Challenging Diagnosis of Interstitial Lung Disease in Patients with Autoimmune Diseases
Verónica Pulito-Cueto¹, Sara Remuzgo-Martinez², Fernanda Genre Romero², Belén Atienza-Mateo³, Victor Mora-Cuesta⁴, David Iturbe-Fernández⁴, Leticia Lera-Gómez⁵, María Sebastián-Mora¹, Virginia Portilla¹, Alfonso Corrales¹, Ricardo Blanco¹, Jose Cifrian⁶, Miguel A Gonzalez-Gay⁷ and Raquel López-Mejías¹, ¹Rheumatology Department, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, ²IDIVAL, Santander, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴Immunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL; Department of Pneumology, Marqués de Valdecilla University Hospital, Santander, Spain, ⁵Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁶Immunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL; Department of Pneumology, Marqués de Valdecilla University Hospital; School of Medicine, Cantabria University, Santander, Spain, ⁷IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) constitutes one of the most critical comorbidities in autoimmune diseases (AD), particularly in rheumatoid arthritis (RA) and systemic sclerosis (SSc)…
Abstract Number: 0624 • ACR Convergence 2023
Outcomes in Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Based on Serological Profiles: Focus on Anti-Centromere Antibody (ACA) and Anti-RNA Polymerase III (ARA) Antibodies
Elizabeth Volkmann¹, Shervin Assassi², Christopher Denton³, Rozeta Simonovska⁴, Steven Sambevski⁵ and Elana Bernstein⁶, ¹University of California Los Angeles, Los Angeles, CA, ²University of Texas McGovern Medical School at Houston, Houston, TX, ³University College London, London, United Kingdom, ⁴Mainanalytics GmbH, Sulzbach (Taunus), Sulzbach, Germany, ⁵Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, ⁶Division of Rheumatology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY
Background/Purpose: Autoantibody profiles are associated with organ involvement and outcomes in patients with SSc. Anti-topoisomerase I antibody (ATA) positivity has been associated with a greater…
Abstract Number: 0645 • ACR Convergence 2023
Continuous Progressive ILD in Systemic Sclerosis Is Associated with Mortality
Anna-Maria Hoffmann-Vold¹, Liubov Petelytska², Havard Fretheim¹, Trond Mogens Aaløkken³, Mike Becker⁴, Cathrine Brunborg⁵, Cosimo Bruni⁶, Christian Clarenbach⁷, Phuong Phuong Diep⁸, Rucsandra Dobrota⁶, Michael Durheim⁹, Muriel Elhai¹⁰, Thomas Frauenfelder¹¹, Suzana Jordan⁶, Emily Langballe¹², Oyvind Midtvedt¹, Carina Mihai⁶, Oyvind Molberg¹³ and Oliver Distler⁶, ¹Oslo University Hospital, Oslo, Norway, ²Bogomolets National Medical University, Kyiv, Ukraine, ³Dept of Radiology, Oslo University Hospital, Oslo, Norway, ⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁵Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital - Rikshospitalet, Oslo, Norway, ⁶Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁷Dept of Pulmonology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁸Dept of Respiratory diseases, University Hospital Oslo, Oslo, Norway, ⁹Dept of Respiratory diseases, Oslo University Hospital, Oslo, Norway, ¹⁰University Hospital zurich, University of Zurich, Zurich, Switzerland, ¹¹Dept of Radiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ¹²Universitetet i Oslo, Oslo, Norway, ¹³Dept of Rheumatology, University Hospital Oslo, Oslo, Norway
Background/Purpose: We have previously shown that short term progression of interstitial lung disease (ILD) in systemic sclerosis (SSc) is associated with mortality. However, it is…
Abstract Number: 0667 • ACR Convergence 2023
The Risk of Stroke and Myocardial Infarction in Systemic Sclerosis: A Population-based Study
Jiwon Hwang¹, Yeonghee Eun², Kyungdo Han³ and Joong Kyong Ahn², ¹Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, South Korea, ²Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, ³Department of Statistics and Actuarial Science, Soongsil University, Seoul, South Korea
Background/Purpose: Previous studies have suggested a link between systemic sclerosis (SSc) and cardiovascular disease, but large-scale data are still lacking due to the nature of…
Abstract Number: 0941 • ACR Convergence 2023
RUNX1 Expression and Binding Site Accessibility Is Associated with Increased Disease Severity in Systemic Sclerosis
Rezvan Parvizi¹, Zhiyun Gong¹, Dillon Popovich¹, Tamar Abel², Helen Jarnagin¹, Madeline Morrisson¹, Tammara Wood², Jonathan Garlick³, Monique Hinchcliff⁴, Patricia Pioli¹ and Michael Whitfield¹, ¹Geisel School of Medicine at Dartmouth, Hanover, NH, ²Dartmouth College, Hanover, NH, ³Tufts University School of Dental Medicine, Boston, MA, ⁴Yale School of Medicine, Westport, CT
Background/Purpose: Runt-related transcription factor 1 (RUNX1) is a member of the core-binding factor family that regulates proliferation, differentiation, and cell survival in multiple cell lineages.…
Abstract Number: 1042 • ACR Convergence 2023
B-line of Lung Ultrasound Reflects Different Morphological Features on Chest HRCT Between Interstitial Lung Disease Associated with Systemic Sclerosis and Myositis
Shinji Watanabe¹, Keina Yomono², Shintaro Yamamoto¹, Mikito Suzuki³, Takahisa Gono⁴ and Masataka Kuwana⁴, ¹Nippon Medical School, Tokyo, Japan, ²Nippon Medical School University, Tokyo, Japan, ³Nippon Medical School Hospital, Tokyo, Japan, ⁴Nippon Medical School Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Lung ultrasound (LUS) is a non-invasive imaging tool to evaluate distribution and severity of interstitial lung disease (ILD). Utility of LUS has been examined…
Abstract Number: 1623 • ACR Convergence 2023
Diffuse Juvenile Systemic Sclerosis Patients Show Distinct Organ Involvement, Antibody Pattern and Have More Severe Disease in the Largest jSSc Cohort of the World. Results from the Juvenile Scleroderma Inception Cohort
Ivan Foeldvari¹, Jens Klotsche², Kathryn Torok³, Ozgur Kasapcopur⁴, Amra Adrovic⁵, Brian Feldman⁶, FLAVIO SZTAJNBOK⁷, Maria Teresa TErreri⁸, Ana Sakamoto⁹, Sindhu Johnson¹⁰, Jordi Anton¹¹, Valda Stanevica¹², Raju Khubchandani¹³, Dieneke Schonenberg-Meinema¹⁴, Eslam Al-Abadi¹⁵, Ekaterina Alexeeva¹⁶, Maria Katsikas¹⁷, Sujata Sawhney¹⁸, Vanessa Smith¹⁹, Simone Appenzeller²⁰, Tadey Avcin²¹, Mikhail Kostik²², Thomas Lehman²³, Hana Malcova²⁴, Edoardo Marrani²⁵, Clare Pain²⁶, Natalia Vasquez-Canizares²⁷, Patricia Costa Reis²⁸, Mahesh Janarthanan²⁹, Maria Jose Santos³⁰, Sima Abu Alsaoud³¹, Christina Battagliotti³², Lillemor Berntson³³, blanca e r bica³⁴, Juergen Brunner³⁵, Daniela Kaiser³⁶, Dragana Lazarevic³⁷, Kirsten Minden³⁸, Farzana Nuruzzaman³⁹, Siri Opsahl Hetlevik⁴⁰, Yosef Uziel⁴¹ and Nicola Helmus⁴², ¹Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ²German Rheumatism Research Center, Berlin, Germany, ³University of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, ⁵Istanbul University - Cerrahpasa, Istanbul, Turkey, ⁶The Hospital for Sick Children, Toronto, ON, Canada, ⁷UFRJ/UERJ, São Paulo, Brazil, ⁸UNIFESP, São Paulo, Brazil, ⁹Federal University of São Paulo (UNIFESP), São Paulo, Brazil, ¹⁰Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada, ¹¹Hospital Sant Joan de Déu, Pediatric Rheumatology Department, Universitat de Barcelona, Barcelona, Spain, ¹²Children's Clinical University Hospital, Zemgales priekšpilseta, Riga, Latvia, ¹³SRCC Childrens Hospital, Mumbai, India, ¹⁴Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, ¹⁵Birmingham Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom, ¹⁶Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia, ¹⁷Hospital de Pediatria Juan P Garrahan, Servicio de Inmunologia/Reumatologia, Buenos Aires, Argentina, ¹⁸Sir Ganga Ram Hospital, Uttar Pradesh, India, ¹⁹Ghent University Hospital, Gent, Belgium, ²⁰UNICAMP, Campinas, Brazil, ²¹University Children's Hospital University Medical Center Ljubljana, Ljubljana, Slovenia, ²²Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, ²³Hospital for Special Surgery, New York, NY, ²⁴Motol University Hospital, Prague, Czech Republic, ²⁵University of Florence, Firenze, Italy, ²⁶Alder Hey NHS Trust, Liverpool, United Kingdom, ²⁷Children’s Hospital at Montefiore, Bronx, NY, ²⁸Hospital de Santa Maria, Lisbon, Portugal, ²⁹SRI RAMACHANDRA INSTITUTE OF HIGHER EDUCATION AND RESEARCH, Chennai, India, ³⁰Hospital Garcia de Orta, Almada, Lisboa, Portugal, ³¹Caritas baby Hospital, East Jerusalem, Israel, ³²Hospital de Niños Dr Orlando Alassia, Santa Fe, Argentina, ³³Dept. of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden, ³⁴Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, ³⁵Medical University Innsbruck; Department of Pediatrics, Pediatric Rheumatology, Innsbruck, Austria, ³⁶Children's Hospital Lucerne, Lucerne, Switzerland, ³⁷Dept of Pediatric Rheumatology and Immunology Clinical Center Nis, Faculty of Medicine, University of Niš, Nis, Serbia, ³⁸Charité University Medicine and German Rheumatism Research Center Berlin, Berlin, Germany, ³⁹Stony Brook Children's Hospital, Stony Brook, NY, ⁴⁰Oslo University Hospital, Oslo, Norway, ⁴¹Pediatric Rheumatology Unit, Meir Medical Center, Kfar Saba, Sackler School of Medicine, Tel Aviv University, Kfar Saba, Israel, ⁴²Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany
Background/Purpose: Juvenile systemic sclerosis (jSSc) is an orphan disease with a prevalence of 3 in 1,000,000 children. In adult patients there are significant differences between…
Abstract Number: 2353 • ACR Convergence 2023
Role of Insulin-like Growth Factor Binding Protein-7 (IGFBP7) in Pulmonary Hypertension Pathogenesis and as a Biomarker Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Ye Jin Jeong¹, Soumyaroop Bhattacharya¹, Maria de la Luz Garcia-Hernandez², Javier Rangel-Moreno¹, Qingfu Xu³ and Benjamin Korman¹, ¹University of Rochester, Rochester, NY, ²University of Rochester, West Henrietta, NY, ³CanSino Biologic Inc., Tianjin, China
Background/Purpose: Systemic sclerosis (SSc, scleroderma) is an autoimmune connective tissue disease that causes autoimmunity, vascular dysfunction, and fibrosis of the skin, lungs, and other organs.…

« Previous Page
1
…
8
9
10
11
12
…
46
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.